NAD reviews Natrol’s BioSil
This article was originally published in The Tan Sheet
Executive Summary
Natrol provided "reasonable support" for claims it made for its liquid dietary supplement BioSil, which is indicated to promote the health of skin, hair, nails and bones in women, but the firm should modify or discontinue certain claims, according to an Oct. 21 National Advertising Division decision. NAD said Natrol, a subsidiary of India-based Plethico Pharmaceuticals, substantiated some claims with three double-blind, placebo-controlled clinical trials. However, NAD recommended the firm discontinue the claims that BioSil "reduced fine lines and wrinkles by 19 percent" and that the product is "clinically proven to give a more youthful look" in 20 weeks. Natrol said while it disagrees with NAD that some of its claims are overly broad, it will comply with the recommendations